|Systematic (IUPAC) name|
|Legal status||℞ Prescription only
Not available in U.S. or Canada
|Metabolism||Hepatic (CYP involved)|
|Half-life||2.95 ± 1.19 hours|
|Excretion||Renal, very low|
|ATC code||P01 QP51|
|Mol. mass||287.293 g/mol|
|(what is this?)|
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Nifurtimox has been used to treat Chagas disease, when it is given for 30 to 60 days, but gastrointestinal and neurological side effects have meant that benznidazole is now preferred for that indication.
Nifurtimox has also been used to treat African trypanosomiasis (sleeping sickness), and is active in the second stage of the disease (CNS involvement). When nifurtimox is given on its own, about half of all patients will relapse, but the combination of melarsoprol with nifurtimox appears to be efficacious. Trials are awaited comparing melarsoprol/nifurtimox against melarsoprol alone for African sleeping sickness.
Combination therapy with eflornithine and nifurtimox is safer and easier than treatment with eflornithine alone, and appears to be equally or more effective. It has been recommended as first-line treatment for second-stage African trypanosomiasis.
Side effects, contraindications and interactions
|This section is empty. You can help by adding to it. (January 2013)|
Nifurtimox is dosed as 15 mg/kg/day in two to three divided doses. It is given by mouth. Refer to the articles on Chagas disease and sleeping sickness for more detailed information on dosing for these diseases.
Manufacturing and availability
Nifurtimox is sold as Lampit by Bayer. It was previously known as Bayer 2502.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- Coura JR, de Castro SL. (2002). "A critical review of Chagas disease chemotherapy". Mem Inst Oswaldo Cruz 97 (1): 3–24. doi:10.1590/S0074-02762002000100001. PMID 11992141.
- Pepin J, Milord F, Mpia B, et al. (1989). "An open clinical trial of nifurtimox for arseno-resistant T.b. gambiense sleeping sickness in central Zaire". Trans R Soc Trop Med Hyg 83 (4): 514–7. doi:10.1016/0035-9203(89)90270-8. PMID 2694491.
- Bisser S, N'Siesi F-X, Lejon V, et al. (2007). "Equivalence Trial of Melarsoprol and Nifurtimox Monotherapy and Combination Therapy for the Treatment of Second-Stage Trypanosoma brucei gambiense Sleeping Sickness". J Infect Dis 195 (3): 322–329. doi:10.1086/510534. PMID 17205469.
- Pepin J (2007). "Combination Therapy for Sleeping Sickness: A Wake-Up Call". J Infect Dis 195 (3): 311–13. doi:10.1086/510540. PMID 17205466.
- Priotto G, Kasparian S, Mutombo W, et al. (July 2009). "Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial". Lancet 374 (9683): 56–64. doi:10.1016/S0140-6736(09)61117-X. PMID 19559476.
- ClinicalTrials.gov NCT00601003 . Retrieved on July 10, 2009.